PMID- 34969653
OWN - NLM
STAT- MEDLINE
DCOM- 20220215
LR  - 20220531
IS  - 1989-4805 (Electronic)
IS  - 1889-1837 (Linking)
VI  - 39
IP  - 1
DP  - 2022 Jan-Mar
TI  - Monocyte chemoattractant protein-1 and hypertension: An overview.
PG  - 14-23
LID - S1889-1837(21)00074-X [pii]
LID - 10.1016/j.hipert.2021.11.003 [doi]
AB  - BACKGROUND: The association between hypertension and cardiovascular disease (CVD) 
      has been increasingly studied through early inflammatory biomarkers. The monocyte 
      chemoattractant protein-1 (MCP-1) is the main chemokine implicated in the 
      inflammatory endothelial process, attracting monocytes and macrophages to the 
      atherosclerotic plaque. METHODS: We reviewed the main observational studies that 
      have analyzed serum MCP-1 in patients with hypertension regardless of CVD, 
      relating them to target organ damage (TOD). RESULTS: As endothelial dysfunction 
      continues and TOD accumulates, MCP-1 has been perpetuated at higher levels. The 
      relationship between this chemokine and the increase in comorbidities, such as 
      chronic kidney disease, dyslipidaemia, diabetes, and coronary artery disease, 
      became clearer from the observational studies. However, patients with such 
      morbidities use medications with potential anti-inflammatory effects. CONCLUSION: 
      There is no normal threshold of MCP-1 for the healthy population, nor a uniform 
      curve pattern, due to a balance between genetic factors, age, gender, 
      comorbidities, TOD, and anti-inflammatory effects of drugs. In fact, MCP-1 seems 
      to have a promising role as a tool for further improvement in cardiovascular risk 
      stratification, as prognostic studies have demonstrated an association with fatal 
      and non-fatal cardiovascular outcomes, regardless of other clinical and 
      laboratory predictors.
CI  - Copyright (c) 2021 SEH-LELHA. Publicado por Elsevier Espana, S.L.U. All rights 
      reserved.
FAU - Cortez, A
AU  - Cortez A
AD  - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil. Electronic 
      address: arthurfcortez@gmail.com.
FAU - Muxfeldt, E
AU  - Muxfeldt E
AD  - Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211227
PL  - Spain
TA  - Hipertens Riesgo Vasc
JT  - Hipertension y riesgo vascular
JID - 101510649
RN  - 0 (Biomarkers)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
SB  - IM
MH  - Biomarkers
MH  - *Cardiovascular Diseases/epidemiology
MH  - Chemokine CCL2
MH  - Humans
MH  - *Hypertension/drug therapy/epidemiology
OTO - NOTNLM
OT  - Cardiovascular disease
OT  - Chemokine
OT  - Enfermedad cardiovascular
OT  - Hipertension
OT  - Hipertension resistente
OT  - Hypertension
OT  - Inflamacion
OT  - Inflammation
OT  - Monocyte chemoattractant protein-1
OT  - Proteina 1 quimioatrayente de monocitos
OT  - Quimioquina
OT  - Resistant hypertension
EDAT- 2022/01/01 06:00
MHDA- 2022/02/16 06:00
CRDT- 2021/12/31 05:36
PHST- 2021/07/29 00:00 [received]
PHST- 2021/11/10 00:00 [revised]
PHST- 2021/11/16 00:00 [accepted]
PHST- 2022/01/01 06:00 [pubmed]
PHST- 2022/02/16 06:00 [medline]
PHST- 2021/12/31 05:36 [entrez]
AID - S1889-1837(21)00074-X [pii]
AID - 10.1016/j.hipert.2021.11.003 [doi]
PST - ppublish
SO  - Hipertens Riesgo Vasc. 2022 Jan-Mar;39(1):14-23. doi: 
      10.1016/j.hipert.2021.11.003. Epub 2021 Dec 27.